JP6716468B2 - 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 - Google Patents

肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 Download PDF

Info

Publication number
JP6716468B2
JP6716468B2 JP2016566672A JP2016566672A JP6716468B2 JP 6716468 B2 JP6716468 B2 JP 6716468B2 JP 2016566672 A JP2016566672 A JP 2016566672A JP 2016566672 A JP2016566672 A JP 2016566672A JP 6716468 B2 JP6716468 B2 JP 6716468B2
Authority
JP
Japan
Prior art keywords
resveratrol
ursolic acid
administered
composition
res
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016566672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514858A5 (OSRAM
JP2017514858A (ja
Inventor
トーマス ジェイ． スラガ
トーマス ジェイ． スラガ
ジェイコブ ジュンコ
ジェイコブ ジュンコ
フイユン リャン
フイユン リャン
サラ レイナ
サラ レイナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2017514858A publication Critical patent/JP2017514858A/ja
Publication of JP2017514858A5 publication Critical patent/JP2017514858A5/ja
Application granted granted Critical
Publication of JP6716468B2 publication Critical patent/JP6716468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016566672A 2014-05-05 2015-05-05 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 Active JP6716468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988859P 2014-05-05 2014-05-05
US61/988,859 2014-05-05
PCT/US2015/029224 WO2015171598A1 (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020100600A Division JP2020147590A (ja) 2014-05-05 2020-06-10 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物

Publications (3)

Publication Number Publication Date
JP2017514858A JP2017514858A (ja) 2017-06-08
JP2017514858A5 JP2017514858A5 (OSRAM) 2018-06-14
JP6716468B2 true JP6716468B2 (ja) 2020-07-01

Family

ID=54392898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016566672A Active JP6716468B2 (ja) 2014-05-05 2015-05-05 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物
JP2020100600A Pending JP2020147590A (ja) 2014-05-05 2020-06-10 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020100600A Pending JP2020147590A (ja) 2014-05-05 2020-06-10 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物

Country Status (6)

Country Link
US (7) US10155003B2 (OSRAM)
EP (1) EP3139910B1 (OSRAM)
JP (2) JP6716468B2 (OSRAM)
AU (2) AU2015256178B2 (OSRAM)
MY (1) MY181685A (OSRAM)
WO (1) WO2015171598A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3139910B1 (en) * 2014-05-05 2019-11-27 The Board of Regents of The University of Texas System Compositions comprising ursolic acid and/or resveratrol for treating obesity
US11135145B2 (en) 2015-11-13 2021-10-05 Paul John Thornally Hesperetin and trans-resveratrol compositions and methods thereof
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
JP2020526594A (ja) 2017-07-13 2020-08-31 イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー Ｐｄ−１を標的とするサポニン系化合物及びその応用
IL273078B2 (en) * 2017-09-13 2025-06-01 Emmyon Inc Ursolic acid morpholine and diethanolamine salts
WO2023091668A1 (en) * 2021-11-18 2023-05-25 Board Of Regents, The University Of Texas System Combinations of curcumin and ursolic acid and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7772195B2 (en) 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
EP2040696B1 (en) * 2006-07-14 2017-01-25 DSM IP Assets B.V. Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders
BRPI0806774A2 (pt) * 2007-01-16 2011-09-13 Ipintl Llc composição para tratamento de sìndrome metabólica
CN101032564B (zh) * 2007-02-28 2011-03-23 天津津酒集团有限公司 调节血脂养生酒及其制备方法
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
MY163031A (en) * 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
US9393221B2 (en) * 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage
WO2014014530A1 (en) 2012-07-17 2014-01-23 Mylari Banavara L Ursolic acid salts for treating diabetes and obesity
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
EP3139910B1 (en) * 2014-05-05 2019-11-27 The Board of Regents of The University of Texas System Compositions comprising ursolic acid and/or resveratrol for treating obesity
NZ728488A (en) * 2014-07-29 2023-03-31 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Also Published As

Publication number Publication date
EP3139910A4 (en) 2017-11-29
AU2015256178B2 (en) 2020-02-27
AU2015256178A1 (en) 2016-11-24
US20190192537A1 (en) 2019-06-27
US20220226347A1 (en) 2022-07-21
US11690851B2 (en) 2023-07-04
US11166962B2 (en) 2021-11-09
US10155003B2 (en) 2018-12-18
MY181685A (en) 2020-12-31
AU2020203419B2 (en) 2021-05-13
US20170056414A1 (en) 2017-03-02
US20200330480A1 (en) 2020-10-22
US11090311B2 (en) 2021-08-17
AU2020203419A1 (en) 2020-06-11
US11684626B2 (en) 2023-06-27
US20220023241A1 (en) 2022-01-27
US10583145B2 (en) 2020-03-10
EP3139910A1 (en) 2017-03-15
JP2017514858A (ja) 2017-06-08
WO2015171598A1 (en) 2015-11-12
US20210252016A1 (en) 2021-08-19
EP3139910B1 (en) 2019-11-27
US20200323879A1 (en) 2020-10-15
US11642354B2 (en) 2023-05-09
JP2020147590A (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
US11642354B2 (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
Verma et al. Obesity and diabetes: an update
Milic et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
CN102630161A (zh) 通过用岩藻黄质和石榴油酸的组合激活去乙酰化酶Sirtuin来延缓衰老过程的方法
US20250000878A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
Nainu et al. Natural products targeting inflammation-related metabolic disorders: A comprehensive review
Fawzy et al. Eugenol modulates insulin sensitivity by upregulating insulin receptor substrate-2 in non-alcoholic fatty liver disease in rats
Ziółkiewicz et al. Potential of chlorogenic acid in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): animal studies and clinical trials—a narrative review
Park et al. Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model
Li et al. Co‐administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1
JP2020535222A (ja) 満腹および／または食欲に関与するペプチドレベルの調節による体重管理のための組成物
JP2016027012A (ja) Ｕｃｐ−１発現促進剤
US9597307B2 (en) Sulforaphane for treating or reducing insulin resistance of the liver
ES2992157T3 (es) Composición oral que comprende b-escina y el uso de la misma
Fomusi Ndisang Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Szydełko et al. Health-promoting properties of compounds derived from Capsicum sp. A review
US12280084B1 (en) Fenugreek formulation for lowering blood glucose and weight loss
Apte Anti-diabetic effects of excipients: possibility of formulation of an anti-diabetic dosage form using pharmaceutical excipients or their constituents, or food additives
Landrier et al. Tomatoes and lycopene: Inflammatory modulator effects
AU2019479023B2 (en) Composition and method for the prevention and treatment of obesity
US10758519B2 (en) UCP-1 expression promoter
WO2015199097A1 (ja) Ｕｃｐ－１発現促進剤
Cyclophosphamide-Induced Poster Communications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200610

R150 Certificate of patent or registration of utility model

Ref document number: 6716468

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250